X

Trial Profile

A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary) ; Sapanisertib (Primary)
Indications Anal cancer; Cervical cancer; Gynaecological cancer; Human papillomavirus infections; Oropharyngeal cancer; Penile cancer
Focus Adverse reactions

Most Recent Events

24 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
22 Jul 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.
22 Jul 2016 Planned initiation date changed from 1 Aug 2016 to 1 Sep 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com